61 results
8-K
EX-99.1
INBS
Intelligent Bio Solutions Inc
17 Nov 21
GBS Inc. Reports First Quarter 2022 Financial Results and Recent Business Highlights
4:05pm
its clinical trial strategy and protocols and accordingly filed a Pre-Submission package on behalf of the group with the United States (US) Food … and Drug Administration (FDA). The purpose of this pre-submission is to confirm with the FDA the GBS regulatory strategy and proposed clinical studies
8-K
EX-99.1
INBS
Intelligent Bio Solutions Inc
11 Aug 21
GBS Inc. Reports Fourth Quarter and Full Year 2021 Preliminary Financial Results and Recent Business Highlights
4:00pm
Manufacturing Strategy.”
Fourth Quarter & FY Highlights and Recent Operational Developments
Financial Stability
$4.7 Million Medical Products Priority Grant … for clinical strategy in support of regulatory, commercial and marketing services measures
Harvard University’s Wyss Institute collaboration to develop
8-K
EX-99.1
INBS
Intelligent Bio Solutions Inc
12 May 23
Intelligent Bio Solutions Inc. Reports Fiscal 2023 Third Quarter
5:20pm
regulatory path forward for our Intelligent Fingerprinting Drug Screening Cartridge, a key step in our U.S. expansion strategy. More recently, we were … Solutions to determine the most suitable FDA regulatory pathway as part of the Company’s strategy for expansion into the U.S. market.
In April 2023, INBS
8-K
EX-99.1
INBS
Intelligent Bio Solutions Inc
3 Nov 21
GBS Inc. Announces Executive Leadership Changes to Accelerate Product Development and Manufacturing
5:01pm
was instrumental in establishing and securing funding for the NSW biotechnology strategy, BioFirst, a $150 (AUD) million investment.
About GBS Inc.
GBS Inc
8-K
EX-99.1
INBS
Intelligent Bio Solutions Inc
21 Jun 23
Intelligent Bio Solutions Receives Non-Dilutive Grant Funding of USD $1.43 Million
2:30pm
identified the project as one of six National Manufacturing Priorities under the Modern Manufacturing Strategy (MMS).
“We are grateful for the continued
8-K
EX-99.1
sspqs4n2guu
14 Oct 21
GBS Inc. Announces its Pre-Submission package is with the FDA
12:00pm
8-K
w8dddc8f nw9
3 Nov 21
GBS Inc. Announces Executive Leadership Changes to Accelerate Product Development and Manufacturing
5:01pm
8-K
EX-99.1
kj3xlaj nwyi0
30 Jun 23
Regulation FD Disclosure
4:30pm
8-K
EX-99.1
5t395m71
5 May 23
Regulation FD Disclosure
5:00pm
8-K
EX-99.1
6cw85z
11 Oct 22
GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology
6:07am
S-1/A
EX-10.6
sq5z2qp0yo35qcxb
2 Aug 19
IPO registration (amended)
4:38pm
8-K
EX-99.1
k78hbggzm9cf7kr51a
16 Jun 22
GBS Inc. Enters into Exclusivity Agreement for an Acquisition of
5:46pm
DOS/A
0apbefw4b0h a4bn
28 Sep 18
Draft offering statement (non-public) (amended)
12:00am
8-K
EX-99.1
2m8g6rxmwm
8 Nov 23
Intelligent Bio Solutions Inc. Reports Fiscal 2024 First Quarter Financial Results and Operational Highlights
5:27pm
8-K
EX-99.1
4zw1w quqfj9
9 Feb 24
Intelligent Bio Solutions Inc. Reports Fiscal Second Quarter and Six-Month Financial Results and Operational Highlights
5:05pm
DOS/A
tu8e6vszwe
28 Sep 18
Draft offering statement (non-public) (amended)
12:00am
DOSLTR
e41bvo0m
18 Jun 18
Draft offering statement letter
12:00am
DOS/A
1e56cq3blbi3rvw4mx6
15 Aug 18
Draft offering statement (non-public) (amended)
12:00am
8-K
EX-99.1
bg0au3ttu9bs 74v6eqp
31 Aug 22
Results of Operations and Financial Condition
4:15pm
8-K
EX-99.1
ho3ucn
25 Aug 23
Intelligent Bio Solutions Inc. Reports Fiscal 2023 Fourth Quarter and Full Year Financial Results and Operational Highlights
8:00am